Zami Aberman
2010
In 2010, Zami Aberman earned a total compensation of $559K as Chief Executive Officer at Pluristem Therapeutics, a 4% decrease compared to previous year.
Compensation breakdown
| Salary | $331,917 |
|---|---|
| Stock Awards | $227,068 |
| Total | $558,985 |
Aberman received $331.9K in salary, accounting for 59% of the total pay in 2010.
Aberman also received $227.1K in stock awards.
Rankings
In 2010, Zami Aberman's compensation ranked 7,321st out of 10,439 executives tracked by ExecPay. In other words, Aberman earned more than 29.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 7,321 out of 10,439 | 30th |
Division Manufacturing | 2,696 out of 3,838 | 30th |
Major group Chemicals And Allied Products | 639 out of 921 | 31st |
Industry group Drugs | 432 out of 680 | 37th |
Industry Biological Products, Except Diagnostic Substances | 79 out of 142 | 44th |
Source: SEC filing on April 15, 2011.
Aberman's colleagues
We found one more compensation record of an executive who worked with Zami Aberman at Pluristem Therapeutics in 2010.
2010
Yaky Yanay
Pluristem Therapeutics
Chief Financial Officer
News
Pluristem Therapeutics CEO Yaky Yanay's 2022 pay falls 86% to $1.3M
February 27, 2023
Pluristem Therapeutics Chairman Zami Aberman's 2020 pay falls 54% to $501K
April 8, 2021
Pluristem Therapeutics Chairman Zami Aberman's 2019 pay jumps 85% to $1.1M
May 20, 2020
Pluristem Therapeutics CEO Zami Aberman's 2018 pay falls 83% to $593K
April 25, 2019